

S 5123

Breakthrough Therapies Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: Nov 17, 2022

Current Status: Read twice and referred to the Committee on the Judiciary.

Latest Action: Read twice and referred to the Committee on the Judiciary. (Nov 17, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/5123>

Sponsor

Name: Sen. Booker, Cory A. [D-NJ]

Party: Democratic • **State:** NJ • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Paul, Rand [R-KY]	R · KY		Nov 17, 2022

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	Nov 17, 2022

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

No related bills are listed.

Summary (as of Nov 17, 2022)

Breakthrough Therapies Act

This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.

Actions Timeline

- **Nov 17, 2022:** Introduced in Senate
- **Nov 17, 2022:** Read twice and referred to the Committee on the Judiciary.